On May 23, 15 members of CLSA’s board of directors spent a full day on Capitol Hill meeting with 16 key Members of Congress on issues of importance to California’s biomedical innovation ecosystem.
After a productive day of meetings on May 23 with Members of Congress from the California congressional delegation on Capitol Hill, CLSA hosted our annual Spring Reception at the Folger Shakespeare Library, followed by a private dinner with our Board to recognize three Members of Congress – Ami Bera, M.D. (D-CA-7), Raul Ruiz, M.D. (D-CA-36) and Erik Paulsen (R-MN-3) – as bipartisan recipients of CLSA’s 2018 Visionary Awards for their leadership in promoting thoughtful public policies to advance biomedical research, investment and innovation.
Bipartisan Legislators Named 2018 Visionary Award Recipients for Promoting Policies that Advance Biomedical Innovation at CLSA’s Annual Washington, D.C. Program
Despite California’s significant budget surplus, legislators are continuing to propose burdensome taxes affecting the life sciences industry, among many others. The two tax bills most recently raising alarms among CLSA staff and membership are Senate Bill 993 (Hertzberg) and Assembly Bill 2731 (Gipson).
AB 3087 would create a California commission to set commercial rates for health plans, providers, and hospitals in an attempt to curtail health care costs. CLSA has considered the bill as a blunt instrument for an incredibly complex issue and consequently likely to result in substantial unintended consequences, many of which could impact patient care in California for many years to come.
The Bay Area suffers from the second worst traffic congestion in the country which continues to threaten the region’s economic vitality. There are two upcoming ballot measures that seek to provide some relief.
On May 14, CLSA hosted a congressional briefing on America’s biodefense and emergency preparedness, with a focus on why reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) is critical for ensuring our nation’s biodefense and pandemic preparedness.
This month, CLSA’s Federal Government Relations team participated in the annual BIO Fly-In to advocate for biomedical innovation, investment, and job creation in California. CLSA took part in a total of 18 meetings with bipartisan members of the California Congressional Delegation.
Last year, Governor Brown signed Senate Bill 17 in law, which requires manufacturers to provide a 60-day advance notice of any price increase on a drug to all California public agency purchasers, health insurers, and pharmacy benefit managers (PBM) if that drug’s price has increased 16 percent or more cumulatively over the previous two calendar years, including the current year’s increase.
On April 18, CLSA partnered with the Lawrence Berkeley National Labs and the Council on Competitiveness to provide a briefing to members and staff of the California State Legislature on the status of California’s bioeconomy.